RT Journal Article
SR Electronic
T1 Multicenter cohort study of children hospitalized with SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.19.21251340
DO 10.1101/2021.02.19.21251340
A1 Barton, Michelle
A1 Papenburg, Jesse
A1 Ulloa-Gutierrez, Rolando
A1 Brenes-Chacon, Helena
A1 Yock-Corrales, Adriana
A1 Ivankovich-Escoto, Gabriela
A1 Soriano-Fallas, Alejandra
A1 Mezerville, Marcela Hernandez-de
A1 Bitnun, Ari
A1 Morris, Shaun K.
A1 Tal, Tala El
A1 Yeh, E. Ann
A1 Gill, Peter
A1 Laxer, Ronald M.
A1 Nateghian, Alireza
A1 Aski, Behzad Haghighi
A1 Manafif, Ali
A1 Lefebvre, Marie-Astrid
A1 Caya, Chelsea
A1 Cooke, Suzette
A1 Dewan, Tammie
A1 Restivo, Lea
A1 Viel-Thériault, Isabelle
A1 Trajtman, Adriana
A1 Dwilow, Rachel
A1 Bullard, Jared
A1 Sadarangani, Manish
A1 Roberts, Ashley
A1 Saux, Nicole Le
A1 Bowes, Jennifer
A1 Wong, Jacqueline K.
A1 Purewal, Rupeena
A1 Lautermilch, Janell
A1 Leifso, Kirk
A1 Foo, Cheryl
A1 Newhook, Leigh Anne
A1 Bayliss, Ann
A1 Petel, Dara
A1 Robinson, Joan
A1 on behalf of the Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC)
YR 2021
UL http://medrxiv.org/content/early/2021/02/23/2021.02.19.21251340.abstract
AB Background A cohort study was conducted to describe and compare the characteristics of SARS-CoV-2 infection in hospitalized children in three countries.Methods This was a retrospective cohort of consecutive children admitted to 15 hospitals (13 in Canada and one each in Iran and Costa Rica) up to November 16, 2020. Cases were included if they had SARS-CoV-2 infection or multi-system inflammatory syndrome in children (MIS-C) with molecular detection of SARS-CoV-2 or positive SARS-CoV-2 serology.Results Of 211 included cases (Canada N=95; Costa Rica N=84; Iran N=32), 103 (49%) had a presumptive diagnosis of COVID-19 or MIS-C at admission while 108 (51%) were admitted with other diagnoses. Twenty-one (10%) of 211 met criteria for MIS-C. Eighty-seven (41%) had comorbidities. Children admitted in Canada were older than those admitted to non-Canadian sites (median 4.1 versus 2.2 years; p<0.001) and less likely to require mechanical ventilation (3/95 [3%] versus 15/116 [13%]; p<0.05). Sixty-four of 211 (30%) required supplemental oxygen or intensive care unit (ICU) admission and 4 (1.9%) died. Age < 30 days, admission outside Canada, presence of at least one comorbidity and chest imaging compatible with COVID-19 predicted severe or critical COVID-19 (defined as death or need for supplemental oxygen or ICU admission).Conclusions Approximately half of hospitalized children with confirmed SARS-CoV-2 infection or MIS-C were admitted with other suspected diagnoses. Disease severity was higher at non-Canadian sites. Neonates, children with comorbidities and those with chest radiographs compatible with COVID-19 were at increased risk for severe or critical COVID-19.Main points Approximately half of hospitalized children with laboratory confirmed MIS-C or SARS-CoV-2 infection were admitted with another primary diagnoses. The severity of disease was higher in the middle income countries (Costa Rica and Iran) than in Canada.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the following ethics review boards: Comite Etico Cientifico Hospital Nacional de Ninos, San Jose, Costa Rica (CEC-HNN-030-2020), Iran University of Medical Sciences Ethics Review Committee (IR.IUMS.REC.1399.187), The Hospital for Sick Children Research Ethics Board (#1000070091), Pediatric Panel of the Research Ethics Board of the Research Institute of the McGill University Health Centre (#MP-37-2021-6561), Conjoint Health Research Ethics Board, University of Calgary (REB20-0594), Childrens Hospital of Eastern Ontario Research Ethics Board (CHEOREB# 20/32X), University of British Columbia Children's and Women's Research Ethics Board (# H20-00977), Health Research Ethics Board, University of Manitoba (HSC23858), University of Saskatchewan Biomedical Research Ethics Board (Study 1921), Hamilton Integrated Research Ethics Board, Centre Hospitalier Universitaire de Quebec-Universite Laval (37-2021-6561), and Health Research Ethics Board, University of Alberta (Pro00099426).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding author.